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The burden of renal disease in human immunodeficiency
virus (HIV) and AIDS patients living in Africa is adversely
influenced by inadequate socio-economic and health care
infrastructures. Acute kidney injury in HIV-positive patients,
mainly as a result of acute tubular necrosis, may arise
from a combination of hemodynamic, immunological, and
toxic insult. A variety of histopathological forms of chronic
kidney disease is also seen in HIV patients; HIV-associated
nephropathy (HIVAN) and immune complex disease may
require different treatment strategies, which at present are
unknown. The role of host and viral genetics is still to be
defined, especially in relation to the different viral clades
found in various parts of the world and within Africa.
The arrival and availability of highly active antiretroviral
therapy in Africa has given impetus to research into the
outcome of the renal diseases that are found in those with
HIV. It has also generated a new look into policies governing
dialysis and transplantation in this group where previously
there were none.
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Sub-Saharan Africa has the greatest burden of human
immunodeficiency virus (HIV) in the world with an
estimated 22 million people living with AIDS. In South
Africa, more than 5.7 million people are infected with HIV
with a reported prevalence of 18.8% in economically active
adults1 (Figure 1). The spread of HIV/AIDS in Africa is
directly related to powerful socio-economic and political
factors. These include limited availability and access to basic
health care facilities, deficient communication and transpor-
tation infrastructures, and variable availability and access to
highly active antiretroviral therapy (HAART).
In South Africa there has been a 67% rise in deaths related
to nephritis/nephrosis from 1999 to 2006.2 Similar exponen-
tial rises in chronic kidney disease (CKD) are seen elsewhere
in the world and are related to the rising prevalence of type 2
diabetes and hypertension.2 However, the situation in Africa
is more complex. The rising prevalence of CKD in South
Africa may causally be linked to the rising burden of a new
HIV infection and HIV-related kidney disease. Despite the
enormity of the HIV problem in Africa, much of our
understanding about HIV and kidney pathology comes from
studies undertaken in developed countries. This is beginning
to change as there has been a recent surge of interest from
African researchers who have identified the shortcomings in
evidence-based management protocols to slow the progres-
sion of kidney disease in HIV.
Table 1 lists the causes of renal failure in the categories of
acute disease, acute-on-chronic, and CKD, as seen frequently
at Groote Schuur Hospital in Cape Town. Our experience has
furthermore revealed that approximately 20% of acute
presentations of renal failure have HIV-associated nephro-
pathy (HIVAN) as the predominant underlying pathology.
Also, roughly 20% of all patients with HIVAN have an
additional acute component on renal biopsy (Wearne,
unpublished data). In this paper, we will attempt to review
the acute and chronic HIV-related kidney diseases from a
typical African perspective and the associated challenges and
opportunities that this disease presents to researchers and
healthcare workers in this field.
AKI IN HIV-RELATED KIDNEY DISEASES
The critical challenge of acute kidney injury (AKI) in Africa is
the development of a practical clinical approach that is both
relevant to the continent, given its numerous resource limits,
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as well as adequate to treat a large number of patients. With
the rapid escalation in the demand for overburdened public
healthcare and laboratory services seen in most African states,
serum creatinine measurements are only performed when
patients are hospitalized for acute presentations and rarely in
stable HIV patients before HAART initiation. Early detection
of acute as well as chronic renal disease is thus hindered and
specific preventive therapy is not instituted on time. Mulenga
et al.3 has reported on the importance of simple renal
function screening in an African setting showing high 90-day
mortality for all degrees of detected renal insufficiency when
compared with HIV patients with normal renal function.
A working definition of AKI in these circumstances is
applied such that acutely unwell patients who are azotemic
(with or without oliguria) are diagnosed with AKI until
proven otherwise. Recovery of azotemia with increase in
urine output is sufficient proof for acute tubular necrosis in
most clinical settings. Failure of full recovery, which may
include continued dependency on dialysis therapy, is
considered as proof of chronic or end stage disease.4
Ultrasound evaluation of kidney size and renal biopsy is
used in all tertiary institutions in South Africa. These modes
of investigation are, however, seldom accessible in non-
academic public hospitals in Africa.
The ‘RIFLE’ classification for AKI has been applied in
critically ill HIV patients and the scoring correlates
well as a tool for mortality prediction.5,6 RIFLE refers to an
acronym indicating Risk of renal dysfunction, Injury to
the kidney, Failure of kidney function, Loss of kidney
function, and End-stage kidney disease.6 It is ideal in an
African setting, as it requires no more than the monitoring of
urine output to be useful. However, its drawback is the
requirement for a baseline serum creatinine, which is seldom
available.
Acute dialysis therapy for HIV patients at Groote Schuur
Hospital in Cape Town, South Africa has become the most
common indication for acute dialysis since January 2009.
This is in part because of the growing optimism for the long-
term survival of AIDS patients, as more government and
private funding of antiretroviral (ARV) therapy is made
available.
Causes of acute renal failure in HIV
There are no reliable data on the incidence and causes of
acute HIV-related renal disease in Africa. However, a
different pattern of presentation from the developed world
is being observed in Africa. Here, patients are commonly
young black adults who present with overwhelming oppor-
tunistic infections, mainly tuberculosis but also malaria, and
no past history of medical illness.7 These conditions are
commonly seen as concurrent epidemics in certain popula-
tion groups in South Africa. In a review of HIV patients
requiring acute renal support at Groote Schuur Hospital in
Cape Town, South Africa, acute tubular necrosis (defined as
AKI due to sepsis, nephrotoxic drugs, or hypovolemic shock)
was diagnosed clinically in the majority (58%) of black
African patients with an average age of 34 years (in press—
Nephrology). The predominant causes were pulmonary,
gastrointestinal, and malarial sepsis. Renal biopsies per-
formed in this series, however, proved that approximately
20% had underlying HIVAN and approximately 10% had
other histologically proven renal diseases. Amongst the latter
were diabetic nephropathy, membranous glomerulonephritis,
malignant hypertension, drug-related acute eosinophilic
interstitial nephropathy, and renal tuberculosis. Less than
HIV prevalence (%)
20.0 to 28.0
10.0 to <20.0
5.0 to <10.0
1.0 to <5.0
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Figure 1 |Human immunodeficiency virus (HIV) prevalence
(%) in adults (15–49 years) in Africa, 2007.
Table 1 | Frequent causes of renal failure in HIV as seen at
Groote Schuur Hospital in Cape Town
Acute Acute-on-chronic Chronic
Sepsis HIVAN with or without immune
complex disease plus:
HIVAN
Malaria HIVAN plus
Rhabdomyolysis ATN glomerulonephritis
Drug Membranous
Granulomatous disease MCGN
Drug toxicity Malignant hypertension IgA
Rifampicin Lymphoma MPGN
Cotrimoxazole
Aminoglycosides Idiopathic FSGS
Hypertensive
nephrosclerosis
Renal TB Diabetic
nephropathy
Glomerulonephritis
Pyelonephritis
ATN, acute tubular necrosis; FSGS, focal segmental glomerulosclerosis; HIV, human
immunodeficiency virus; HIVAN, HIV-associated nephropathy; IgA, immunoglobulin
A; MCGN, mesangiocapillary glomerulonephritis; MPGN, mesangial proliferative
glomerulonephritis; TB, tuberculosis.
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20% of this group was on HAART at the time of AKI. AKI in
HAART naı¨ve patients has been reported to carry a sixfold
higher risk of in-hospital mortality related to severe
immunosuppression, high viremia, and late commencement
of HAART.7
AKI has become a significant cause of morbidity
particularly among indigenous black communities where
males commonly use traditional herbs to enhance sexual
potency.8,9 Herbal remedies are often prescribed by tradi-
tional healers for problems such as AIDS-related abdominal
pain, diarrhea, ‘to clean the stomach or intestines’, or as a
means to eradicate HIV.9,10 An overall mortality of 45.5% was
observed among adult patients presenting with AKI who
report traditional medicine use in South Africa. There was a
higher mortality for HIV-positive as compared with HIV
negative patients in one reported study.8
Mixed infections involving malaria and HIV co-infection
have been reported from Africa, as has hemorrhagic fever,
leptospirosis, typhoid fever, schistosomiasis, and other
parasitic infections causing septicemia and acute tubular
necrosis. HIV and malaria co-infection has been shown to
predispose to more severe acute disease, including acute renal
failure.11 The pathophysiology of the more severe disease is
uncertain although experimental work points to malarial
infection causing a decrease in CD4 T-cell count, possibly
through cytokine release, with a subsequent greater degree of
HIV-related immunosuppression.11
Renal tuberculosis can occur in HIV patients as a part of
disseminated infection. With advanced AIDS, tuberculosis
renal disease has been shown to present insidiously as diffuse
interstitial disease and histologically with less well-formed
granulomas and less caseation.12 Loss of function tends to
occur late in the disease process and is difficult to
differentiate from acute interstitial disease caused by anti-
tuberculous drugs. The first documented report of rifampi-
cin-induced AKI with crescentic glomerulonephritis was
reported from Groote Schuur Hospital in 1987.13 Several case
reports have since been printed, some of which show disease
response to steroid therapy if diagnosed early.14
CKD
Kidney disease associated with HIV was first described in
1984 in African–American and Haitian patients with AIDS.
The histological features were originally described as a unique
form of collapsing focal segmental glomerulosclerosis.15 This
kidney disease is now commonly referred to as HIVAN.
HIVAN can precede the clinical symptoms of AIDS and has
even been documented in acute HIV infection.16,17 If left
untreated, HIVAN has a rapid progression to end-stage renal
disease over the course of weeks to months and has become a
leading cause of end-stage renal disease in HIV.16
A spectrum of CKDs beyond HIVAN is increasingly
recognized, which includes immune complex-mediated
glomerulopathies, thrombotic microangiopathies, and vascu-
litidies. Diabetes and hypertension also feature particularly in
developed countries where ARV therapy is widespread.18
However, despite the enormity of the problem, limited data
are available on the prevalence and impact of HIV-associated
renal disease in Africa.19–21
Table 2 shows unpublished data from Groote Schuur
Hospital (2002–2007). The histological findings of 102
biopsies from predominantly black African patients were
reviewed. We defined HIVAN in this series as focal segmental
glomerulosclerosis with or without collapse, epithelial cell
hyperplasia together with microcystic changes of the tubules,
and varying degrees of interstitial fibrosis and inflammation
(Figure 2a).
Causes of chronic renal failure in HIV
HIVAN. HIV-1 has been proven to infect the glomerular
podocytes, epithelial cells of the tubules, and the collecting
Figure 2 |Renal histology seen in HIV-positive patients with
renal failure. (a) Haematoxylin and eosin (H&E) stain under light
microscopy (LM) showing collapsing focal segmental
glomerulosclerosis, microcystic tubular dilatation, interstitial
plasma-cell infiltrate, and interstitial fibrosis. (b) H&E under LM
showing epithelial cell hypertrophy. (c) Silver methenamine stain
under LM showing thickened basement membranes and
membrane duplication/splitting (mesangiocapillary
glomerulonephritis) with no HIV changes. (d) H&E under high
power LM showing ‘ball-in-cup’ appearance. Arrow¼ball-in-cup.
Table 2 | Summary of renal biopsy findings and clinical data
for HIV-positive patients at Groote Schuur Hospital between
2002–2007
Biopsy findings Number CD4 Proteinuria
Serum
creatinine
HIVAN alone 41 184 0.769 479.5
HIVAN+immune complex
diseases
28 327.9 0.83 283
Immune complex
disease—no HIVAN
13 266 0.71 393
FSGS—without features
of HIV
3
Other 17
Total number of biopsies 102
HIV, human immunodeficiency virus; HIVAN, HIV-associated nephropathy.
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duct.22 Classic HIVAN is primarily the result of virus-
induced podocyte injury, proliferation, and ‘fall-off ’ into
Bowmans space, with subsequent collapse of the glomerular
tuft (Figure 2b).23,24 It may be postulated that the
predominant focus of such cellular involvement in different
areas may account for the histological variations, which
observers have generally classified as HIVAN.
HIVAN is often described as presenting classically in AIDS
with nephrotic range proteinuria and large kidneys on
ultrasound examination. However, nephrotic range protei-
nuria may not be a sensitive marker for HIVAN.25
Furthermore, kidney size has been shown to be a poor
predictor of HIVAN.26 A high viral load is neither a specific
nor a sensitive indicator,27 and although a low CD4 count is
common and expected, it can also occur in patients with well
preserved CD4 counts16 and acute HIV infection.17
Our cohort of patients with features of HIVAN alone had
advanced renal failure (mean serum creatinine of 480 mmol/
l), heavy proteinuria (mean of 0.77 g/mmol), and low CD4
counts (184 cells/mm3). The mean creatinine, proteinuria,
and CD4 counts were, however, not vastly dissimilar in those
with immune complex involvement and other HIV unrelated
conditions (Table 2).
In Africa, we are detecting HIVAN far too late in the
course of the disease. Local data have shown histological
features of HIVAN occurring in patients with persistent
microalbuminuria, normal renal function, and CD4 counts
4200 cells/mm3 (ref. 20). Wyatt et al.28 performed postmortem
examinations in HIV-positive patients and revealed sub-
clinical renal pathology that would not have been predicted
using current diagnostic criteria for CKD. Thus, there is the
need to evaluate more practical and sensitive methods for
diagnosing CKD in HIV, to delay or prevent progression.
Until then we share the opinion that these non-invasive
indicators are unreliable and support the utility of a renal
biopsy, if not contraindicated, to make an accurate
histological diagnosis.
Kopp et al.29 showed that the non-muscle myosin heavy
chain 9 (MYH9) gene is associated with biopsy-proven focal
segmental glomerulosclerosis and HIVAN in African Ameri-
cans. This and other susceptibility alleles, such as the Nphs2
locus in animal models, have been found to produce reactive
changes in podocytes that lead to nephropathy in the
presence of HIV-1 infection.30 Limited studies have also
explored the interaction of human genetic variation with
different clades and recombinant forms of HIV-1. Clade C of
the HIV virus predominates in eastern and southern Africa,
whereas the US and Europe have predominantly Clade B,
which is where most of the research has taken place.31 Herein
could be the explanation for the variability in the rate of
HIV disease progression and response to treatment seen
with various population groups and in different
geographical areas.
HIVAN is imminently treatable, with the possibility of
regression or stabilization, once ARVs have been initiated.32
Earlier and more widespread screening and detection of renal
failure, and persistent microalbuminuria needs to be
implemented in primary health services to detect and treat
this disease appropriately. The concern is that HIVAN can
occur at CD4 counts higher than the current South African
guidelines for initiating ARVs.33 Another concern is that
HIV-1 replication has been shown to persist in its renal
reservoir despite effective suppression of plasma viremia with
HAART.24
Africa has limited data on the long-term outcomes of
patients with HIVAN initiated on HAART. The timing of
HAART initiation and the threshold of renal dysfunction,
beyond which HAART therapy will be ineffective, have to be
established. This information is critical in the African context
given the resource constraints. The current resource limita-
tions prohibit HIV-positive patients who are not on HAART
from being assessed for dialysis and transplantation.34
HIV IMMUNE COMPLEX DISEASE
Renal histology other than HIVAN may account for a third to
half of the cases of renal disease among HIV-infected
patients.35 Szczech et al.36 showed a range of other
histological lesions existing at almost the same frequency as
HIVAN. Our experience at Groote Schuur Hospital is in
agreement and has shown a wide spectrum of pathologies in
our biopsy series. Importantly, we have shown a high
proportion of immune complex glomerulonephritis seen as
either a lone feature in 13.3% of the specimens or in
conjunction with features consistent with HIV in 28.6%
(Figure 2c—mesangiocapillary glomerulonephritis with no
HIV changes). It remains unclear whether HIV is a cause
of these immune complex-mediated glomerulonephritidies.
The entity referred to by Gerntholtz et al.19 as HIV immune
complex kidney disease was described as large subepithelial
deposits associated with a basement membrane reaction
producing a ‘ball-in-cup’ architectural pattern. This was not a
common feature in the Groote Schuur Hospital biopsy series
with only one biopsy fitting this description. We believe this
‘ball-in-cup’ appearance may be a variant of postinfectious or
membranous glomerulonephritis (Figure 2d).
The treatment for immune complex glomerulonephritides
in HIV is unknown. Some small studies with limited follow
up have shown some improvement in membranous and
immune complex nephropathy with HAART.37 Szczech
et al.35 showed that HAART alone was not shown to have a
beneficial effect on renal function in their group of patients
with HIV renal disease other than HIVAN. The immune
complex with HIVAN group is unstudied in relation to the
outcome on HAART therapy. It is therefore crucial that
histological diagnosis is obtained where possible.
THE BAD NEWS OF HIV-RELATED RENAL DISEASE IN AFRICA
HIVAN is commonly asymptomatic until the late phase of
the disease. It is thus feared that the roll-out of ARV may not
necessarily make a major impact on the incidence and
devastating consequences of this condition in an African
context. Most African health systems may simply not possess
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the capacity to accommodate all affected people on dialysis
programs. Furthermore, it is unknown whether ARVs will
impact on the progression or reversal of late onset renal
disease.
The rising death rates due to nephrosis/nephritis in South
Africa are likely also a reflection of the constrained dialysis
and transplant service in the countries’ public sector. Many
patients with end-stage renal disease are sent home to die and
do not receive life saving dialysis or transplantation.
The relevance of Africa as a poverty stricken continent
thus impacts on clinical decision making. This is clearly
shown by comparing expenditure on healthcare in relation to
first world countries. The gross domestic product per capita
of most African countries is less than $1,500 (Table 3). This is
far less than the average annual cost of renal replacement
therapy per patient in South Africa in 2004, estimated at
$9130 for hemodialysis and $8319 for continuous ambula-
tory peritoneal dialysis.34 Most middle and low income
earning individuals cannot afford renal replacement therapies
thus making renal disease in Africa a death sentence. In more
‘developed’ African countries, such as South Africa, a
rationing system, which excluded all HIV-infected patients
from dialysis and renal transplant programs, had been used
as a measure to reduce the cost to the state of renal
replacement therapy.34
There is lack of data and under-reporting of studies on
HIV-infected patients with kidney disease from Africa. This is
because of the limited or absolute shortage of resources
needed to perform or interpret a renal biopsy on which the
diagnosis of HIVAN or other HIV-related renal disease is
based. The data from South Africa have emphasized the
importance of renal biopsy in the diagnosis and management
of HIV renal disease.19,20 There is also the challenge of the
‘high cost’ and need for access to diagnostic tools, which
hinders the performance of good clinical research in Africa.
For instance, the study in Kenya on renal disease in untreated
HIV-infected patients reported a higher prevalence of
abnormal renal function (16.3%) than proteinuria (6.2%),
even though the contrary (higher prevalence of proteinuria)
is to be expected in many renal disease associated with HIV.21
Although this study identified a high prevalence of renal
disease among the untreated HIV-positive population, the
use of a single urine dipstix method is inadequate to evaluate
the prevalence of proteinuria. These and other factors
prohibit African researchers from publishing studies con-
ducted in Africa as the rigors of modern day study method,
and the study design are hard to achieve given these unique
restrictions.21
THE GOOD NEWS OF HIV-RELATED KIDNEY DISEASE
IN AFRICA
Despite the lack of resources, there are important events
worth mentioning, which point to a positive future for the
HIV epidemic in Africa. The most important of these has
been the availability of HAART in many African countries.
The 2008 report on the global AIDS epidemic by the joint
United Nations Program on HIV/AIDS revealed that in most
countries of the world, the provision and use of HAART in
HIV-positive patients has increased significantly between
2004 and 2006. Encouragingly, the increased use and
availability of HAART has been more significant in sub-
Saharan African countries (Table 4 and Figure 3). In
countries, such as Zambia, Cote D’Ivoire, and Malawi, the
building of highly collaborative public–private partnerships
for public healthcare between individual governments and
organizations, such as the US President’s Emergency Plan for
AIDS Relief and the Global Fund to Fight AIDS, Tuberculosis
and Malaria, has seen a steady rise in the number of patients
gaining access to HAART. From limited data available in
Africa, the increased availability of HAART is yielding
Table 3 |World health statistics for 2009: health expenditure
for the year 2006 for selected African countries compared
with Japan, France, and the USA
Country
Total expenditure on
health as % of gross
domestic product
Per capita government
expenditure on health
(PPP int. $)
Benin 4.7 31
Burkina Faso 6.3 41
Cote d’Ivoire 3.8 15
Equatorial Guinea 2.1 509
Gabon 4.5 458
Ghana 5.1 26
Kenya 4.6 32
Malawi 12.9 43
Morocco 5.3 54
Egypt 6.3 132
Nigeria 3.8 18
Rwanda 10.9 38
South Africa 8.0 270
Japan 8.1 2 097
France 11.0 2 727
USA 15.3 3 076
http://www.who.int/entity/whosis/whostat/2009/en/index.html (Last accessed 12
July 2009).
Table 4 | Percentage of adults and children with advanced
HIV infection receiving antiretroviral therapy (ART) in
selected countries in sub-Saharan Africa, 20061
Country
All persons
receiving
ART treatment
Percentage of persons
with advanced HIV
receiving ART (low-high)
Benin 7634 42 (35–53)
Burkina Faso 14,079 31 (25–39)
Cote d’Ivoire 36,348 19 (16–25)
Equatorial Guinea 414 14 (10–19)
Gabon 5278 39 (28–56)
Ghana 9882 12 (9–15)
Kenya 125,026 27 (22–36)
Malawi 59,980 21 (18–27)
Morocco 1370 29 (20–42)
Egypt 205 10 (7–14)
Nigeria 95,008 13 (8–19)
Rwanda 34,636 52 (45–63)
South Africa 324,754 21 (17–28)
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dividends in terms of better renal outcomes in HIV-positive
patients.38–41 In the study by Peters et al.,41 8% and 20% of
508 HIV-positive patients on HAART had abnormal serum
creatinine and creatinine clearance, respectively, at baseline.
After 24 months on HAART, there was a significant decrease
of mean serum creatinine (16%) and significant increase of
mean creatinine clearance (21%) compared with baseline.
As a consequence of the increased availability of HAART,
measures to offer renal replacement therapy in this patient
group, including research into HIV-positive donor to HIV-
positive recipient kidney transplantation, are already in
progress. This positive approach to treatment has been
further supported with the latest announcement on world
AIDS day by the South African government to make HAART
therapy available to patients with CD4 counts o350 cells/
mm3 (previously o200 cells/mm3).42 The increasing use of
HAART has not benefited all patients with advanced pre-
existing renal impairment. This is related to late diagnosis,
occult opportunistic infection, and drug nephrotoxicities
associated with delayed initiation of definitive treatment.3,43
It has led to calls for increased renal function and urine
screening in primary HIV clinics before initiation of the
therapy. This new practice will hopefully yield an increased
awareness and early detection of kidney disease in those
populations.
CONCLUSION
We believe that the epidemic of HIV renal disease in Africa
has arrived but has not been widely announced. HIV-related
AKI in Africa is still a consequence of late presentation,
opportunistic infections, and diarrheal disease associated
with advanced AIDS and is preventable. HIVAN and immune
complex disease is best managed through a preventive
strategy by focusing on extensive ARV drug use at an earlier
stage. With sufficient support, African researchers in this field
may still contribute to further understanding and treatment
of HIV-related kidney disease.
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